Therna Biosciences is a San Francisco-based TechBio company pioneering programmable RNA therapeutics by pairing deep RNA biology with generative AI. Its biology-guided, lab-in-the-loop platform designs precisely engineered mRNA molecules — optimized for translation, stability, immune evasion, and tissue-specific expression — and identifies optimal target sites for ASO and siRNA design. Founded in 2023 by serial biotech entrepreneur Nazli Azimi (CEO) alongside UCSF/Arc Institute RNA scientist Hani Goodarzi and Sasan Amini, the company emerged from stealth in August 2025 with a $10M seed round led by AIX Ventures, Pear VC, and Fusion Fund. In March 2026 it partnered with Charles River to advance single-patient RNA medicines for ultra-rare disorders — designing a lung-fibrosis mRNA candidate in three days — and expanded its leadership team alongside a University of Pennsylvania collaboration. The company is building its therapeutic pipeline and lining up a Series A within roughly 18 months of the seed.

Company Profile

Founders & Key People

Investors

Products

• Generative AI RNA design platform (lab-in-the-loop)
• Engineered mRNA therapeutics
• ASO / siRNA target-site design
• Single-patient RNA medicines for ultra-rare disorders (with Charles River)

Competitors

BiotechRNA TherapeuticsGenerative AITechBioSeed StageRare Disease

Private-company numbers are not real-time. Reflects publicly disclosed valuations from press releases, news reports, and tender offers as of 2025-Q3. Refreshed quarterly.